CJC-1295 5 mg/Ipamorelin 5 mg

CJC-1295/Ipamorelin Blend: The Ultimate Growth Hormone-Releasing Stack

Peptide Hubs presents a premium research-grade blend of CJC-1295 (5mg) and Ipamorelin (5mg) in a single 10mg vial. This powerful combination represents the gold standard in growth hormone secretagogue research, offering synergistic effects that maximize natural growth hormone release while minimizing potential side effects. Our pharmaceutical-grade peptide blend is manufactured in the USA under strict quality control protocols, ensuring researchers receive the most reliable and consistent product available.

Lab Test Report

Effects of CJC-1295/Ipamorelin Blend

The CJC-1295/Ipamorelin blend works through two complementary mechanisms to stimulate robust growth hormone release. CJC-1295 (a GHRH analog) binds to growth hormone-releasing hormone receptors in the pituitary, while Ipamorelin (a ghrelin mimetic) activates the ghrelin receptors. This dual approach creates a powerful synergistic effect, resulting in a significant pulse of endogenous growth hormone that mimics the body's natural secretion patterns. Research indicates this combination may support increased lean muscle mass, enhanced fat metabolism, improved sleep quality, accelerated recovery times, and improved skin elasticity. Unlike other GHRPs, Ipamorelin is highly selective for growth hormone release without stimulating cortisol or prolactin secretion, making this blend particularly valuable for specific research applications. Clinical research on growth hormone secretagogues has demonstrated the efficacy of combination therapies in endocrine research.

Dosage Guidelines

For research purposes, typical dosage of the CJC-1295/Ipamorelin blend ranges between 100-300mcg of the combined peptides per administration. The blend should be reconstituted with bacteriostatic water to ensure stability and purity. Most research protocols administer the compound 1-3 times daily, with common timing including upon waking, pre-workout, and before bedtime to align with natural growth hormone pulses. The 1:1 ratio (5mg CJC-1295:5mg Ipamorelin) provides an ideal balance for stimulating a robust GH release while maintaining the favorable side effect profile of both compounds. Researchers should note that administration on an empty stomach typically yields optimal results due to Ipamorelin's mechanism of action.

Cycle Recommendations

Research cycles for the CJC-1295/Ipamorelin blend typically span 8-16 weeks, followed by a 4-week break to prevent receptor desensitization. The extended cycle length is possible due to the favorable safety profile of both compounds. Researchers often combine this blend with other complementary compounds to target specific physiological processes. Popular research stacks include adding Tesamorelin for targeted fat reduction studies, Melanotan II for pigmentation and libido research, PT-141 for sexual dysfunction research, Delta Sleep Inducing Peptide for sleep architecture studies, and Adenosine for cardiovascular and recovery research. These combinations allow for comprehensive investigation of multiple physiological systems simultaneously.

Possible Side Effects

The CJC-1295/Ipamorelin blend is generally well-tolerated in research settings due to Ipamorelin's selective mechanism of action. Some studies have reported transient side effects including mild flushing, dizziness, or tingling sensations at administration sites, which typically diminish with continued use. Unlike GHRP-6 or GHRP-2, Ipamorelin does not stimulate hunger, making this blend particularly suitable for research protocols where appetite control is important. Additionally, the blend does not cause the water retention associated with exogenous growth hormone administration. As with any research compound, proper laboratory protocols should be followed to ensure safety and accurate results.

Reconstitution and Storage

Proper reconstitution is essential for maintaining peptide integrity. The CJC-1295/Ipamorelin blend should be reconstituted with 1-2mL of bacteriostatic water and gently swirled until clear. Avoid vigorous shaking as this may damage the peptide structures. Reconstituted peptide should be refrigerated and used within 4-6 weeks. Unreconstituted vials remain stable for up to 24 months when stored in a cool, dark place away from moisture and extreme temperatures. For optimal results, researchers should follow strict sterile techniques during handling and administration to prevent contamination.

Synergistic Mechanism of Action

The powerful synergy between CJC-1295 and Ipamorelin makes this blend particularly effective for growth hormone research. CJC-1295 increases the amplitude of growth hormone pulses, while Ipamorelin increases the frequency of these pulses. Together, they create a robust physiological pattern of GH release that closely mimics the body's natural secretion. This combination also helps avoid the receptor desensitization that can occur with single-mechanism compounds. Learn more about this powerful GH-releasing stack CJC-1295/Ipamorelin and its research applications in our comprehensive guide.

Quality Assurance

Every batch of Peptide Hubs CJC-1295/Ipamorelin blend undergoes rigorous third-party testing to verify purity, potency, and sterility. Our manufacturing process complies with strict quality control standards, ensuring researchers receive consistent, pharmaceutical-grade product. Each vial contains precisely 5mg of CJC-1295 and 5mg of Ipamorelin, accurately measured for precise dosing in research applications. Certificate of Analysis is available for research verification purposes.

Frequently Asked Questions